Prevention and treatment of postherpetic neuralgia.
Baron
Ralf
R
Division of Neurological Pain Research and Therapy, Department of Neurology, Universitätsklinikum Schleswig-Holstein, 24105 Kiel, Germany. r.baron@neurologie.uni-kiel.de
Wasner
Gunnar
G
D000328:Adult; D000588:Amines / Q000627:therapeutic use*; D000779:Anesthetics, Local / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002675:Child, Preschool; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D000077206:Gabapentin; D006801:Humans; D007278:Injections, Spinal; D008012:Lidocaine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008775:Methylprednisolone / Q000009:adverse effects / Q000627:therapeutic use*; D051474:Neuralgia, Postherpetic / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
D000588:Amines; D000779:Anesthetics, Local; D000998:Antiviral Agents; D002121:Calcium Channel Blockers; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D008012:Lidocaine; D008775:Methylprednisolone